ABUS
Arbutus Biopharma Corporation
$4.48
-$0.10(-2.22%)
53
Overall
40
Value
66
Tech
55
Quality
Market Cap
$877.98M
Volume
443.19K
52W Range
$2.71 - $5.10
Target Price
$5.25
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $24.9M | $1.5M | $10.7M | $5.9M | $6.0M | $6.9M | $11.0M | $39.0M | $18.1M | $6.2M | ||
| Total Revenue | $23.3M | $1.5M | $10.7M | $5.9M | $6.0M | $6.9M | $11.0M | $39.0M | $18.1M | $6.2M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | $47.5M | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $24.9M | $1.5M | $10.7M | $5.9M | $6.0M | $-40.6M | $11.0M | $39.0M | $18.1M | $6.2M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-127.2M | $-493.1M | $-121.6M | $-95.7M | $-149.9M | $64.7M | $84.5M | $102.2M | $96.2M | $82.5M | ||
| Research & Development | $51.5M | $61.3M | $62.7M | $57.9M | $57.6M | $49.3M | $65.5M | $84.4M | $73.7M | $54.0M | ||
| Research Expense | $51.5M | $61.3M | $62.7M | $57.9M | $57.6M | $49.3M | $65.5M | $84.4M | $73.7M | $54.0M | ||
| Selling, General & Administrative | $26.4M | $39.4M | $16.1M | $16.0M | $17.7M | $14.8M | $17.1M | $17.8M | $22.5M | $22.1M | ||
| General & Administrative Expenses | $26.4M | $39.4M | $16.1M | $16.0M | $17.7M | $14.8M | $17.1M | $17.8M | $22.5M | $22.1M | ||
| Salaries & Wages | $-22.1M | $-39.2M | $-15.1M | $-6.0M | $-6.8M | $200.0K | $300.0K | $200.0K | $9.3M | $9.0M | ||
| Depreciation & Amortization | $589.0K | $1.1M | $2.0M | $2.2M | $2.0M | $2.0M | $1.8M | $1.4M | $1.4M | $1.4M | ||
| Depreciation & Amortization | $589.0K | $1.1M | $2.0M | $2.2M | $2.0M | $2.0M | $1.8M | $1.4M | $1.4M | $1.4M | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | $700.0K | $700.0K | $700.0K | $600.0K | $700.0K | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-53.7M | $-100.3M | $-70.1M | $-70.2M | $-71.3M | $-57.8M | $-73.5M | $-65.5M | $-78.1M | $-76.3M | ||
| EBITDA | $-76.7M | $-488.1M | $-106.4M | $-58.9M | $-162.5M | $-57.8M | $-71.6M | $-61.9M | $-71.4M | $-68.5M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | $261.0K | $226.0K | $2.1M | $4.0M | $2.9M | $1.7M | $459.0K | -- | ||
| Intinc | $-96.0K | $823.0K | $179.0K | $-9.0M | $2.1M | $741.0K | $127.0K | $2.2M | $5.7M | $6.6M | ||
| Net Non-Operating Interest Income/Expense | $-96.0K | $823.0K | $-82.0K | $-9.2M | $3.0K | $-3.3M | $-2.7M | $466.0K | $5.7M | $6.6M | ||
| Gain on Sale of Securities | -- | -- | -- | $24.9M | -- | -- | -- | $100.0K | $100.0K | $100.0K | ||
| Other Income/Expense | $45.3M | $252.7M | $40.8M | $14.8M | $66.2M | $3.0M | $2.0M | $-2.3M | $69.0K | $2.6M | ||
| Other Special Charges | $3.3M | $530.0K | $-22.0K | -- | -- | -- | -- | -- | -- | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $109.4M | -- | -- | $4.8M | $156.0K | $64.0K | -- | -- | $1.1M | $3.7M | ||
| Special Income Charges | $-109.4M | $-138.2M | -- | $-4.8M | $-28.9M | $-64.0K | -- | -- | $-1.1M | $-3.7M | ||
| Impairment of Capital Assets | -- | $138.2M | -- | -- | $22.5M | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-77.3M | $-489.2M | $-108.5M | $-61.1M | $-164.3M | $-59.7M | $-73.4M | $-63.3M | $-72.8M | $-69.9M | ||
| Pre-Tax Income | $-77.3M | $-489.2M | $-108.7M | $-61.3M | $-166.4M | $-63.7M | $-76.4M | $-65.0M | $-72.4M | $-69.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-16.2M | $-105.0M | $-24.3M | $-4.3M | $-12.7M | -- | -- | $4.4M | -- | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-61.1M | $-384.2M | $-84.4M | $-95.7M | $-153.7M | $-63.7M | $-76.2M | $-69.5M | $-72.8M | $-69.9M | ||
| Net Income (Continuing Operations) | $-61.1M | $-384.2M | $-84.4M | $-95.7M | $-153.7M | $-63.7M | $-76.2M | $-69.5M | $-72.8M | $-69.9M | ||
| Net Income (Discontinued Operations) | $-61.1M | $-384.2M | $-84.4M | $-95.7M | $-153.7M | $-63.7M | $-76.2M | $-69.5M | $-72.8M | $-69.9M | ||
| Net Income (Common Stockholders) | $-61.1M | $-384.2M | $-85.3M | $-105.8M | $-164.9M | $-75.9M | $-88.4M | $-69.5M | $-72.8M | $-69.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-62.7M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-127.2M | $-493.1M | $-121.6M | $-95.7M | $-149.9M | $64.7M | $84.5M | $102.2M | $96.2M | $82.5M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $45.5M | $53.1M | $54.7M | $55.3M | $57.1M | $75.8M | $106.2M | $150.9M | $166.0M | $185.6M | ||
| Average Shares Outstanding (Diluted) | $45.5M | $53.1M | $54.7M | $55.3M | $37.0M | -- | $106.2M | $150.9M | $166.0M | $185.6M | ||
| Shares Outstanding | $54.6M | $55.0M | $55.1M | $56.1M | $68.9M | $95.6M | $148.6M | $162.6M | $179.5M | $191.5M | ||
| Basic EPS | $-1.34 | $-7.24 | $-1.56 | $-1.21 | $-0.46 | $-1 | $-0.83 | $-0.46 | $-0.44 | $-0.38 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-1 | $-0.83 | $-0.46 | $-0.44 | $-0.38 | ||
| Diluted EPS | $-1.34 | $-7.24 | $-1.56 | $-1.21 | $-2.89 | $-1 | $-0.83 | $-0.46 | $-0.44 | $-0.38 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-0.83 | $-0.46 | $-0.44 | $-0.38 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | -- | $911.0K | $10.1M | $11.1M | $12.1M | $12.1M | -- | -- | -- | ||
| Earnings from equity interest | -- | -- | -- | $-5.6M | $-22.5M | $-2.5M | -- | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | $-5.6M | $-22.5M | $-2.5M | -- | -- | -- | -- | ||
| Net Income Discontinuous Operations | -- | -- | -- | -- | $3.4M | -- | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | -- | -- | -- | -- | $6.3M | -- | -- | -- | -- | -- | ||
| Other Gand A | $26.4M | $39.4M | $16.1M | $16.0M | $17.7M | $14.8M | $17.1M | $17.8M | $22.5M | $22.1M | ||
| Other Impairment Of Capital Assets | $39.0M | $253.2M | $40.8M | $14.8M | $43.8M | -- | -- | -- | -- | -- | ||
| Other Taxes | $-196.0K | $-145.0K | $-183.0K | $-18.0K | -- | -- | -- | -- | -- | -- | ||
| Otherunder Preferred Stock Dividend | -- | -- | $911.0K | $10.1M | $11.1M | $12.1M | $12.1M | -- | -- | -- | ||
| Preferred Stock Dividends | -- | -- | $911.0K | $10.1M | $11.1M | $12.1M | $12.1M | -- | -- | -- | ||
| Provision For Gain Loss On Disposal | -- | -- | -- | -- | $3.4M | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $26.4M | $39.4M | $16.1M | $16.0M | $17.7M | -- | -- | -- | -- | -- | ||
| Restruct | $109.4M | -- | -- | $4.8M | $156.0K | $64.0K | -- | -- | $1.1M | $3.7M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABUS | $4.48 | -2.2% | 443.19K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Arbutus Biopharma Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW